[Remote] Senior Director, Publications and Medical Communications at Abata Therapeutics

Remote

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

BiotechnologyIndustries

Requirements

Candidates should possess a Bachelor’s degree in a relevant scientific discipline, such as Communications, Journalism, or Marketing, and ideally hold an advanced degree in a related field. A minimum of 10 years of experience in publications and medical communications, particularly within the biotechnology or pharmaceutical industry, is required, along with demonstrated leadership skills and experience managing teams. Strong understanding of medical writing principles, regulatory guidelines, and ICMJE guidelines is essential.

Responsibilities

The Senior Director, Publications and Medical Communications will develop and implement a comprehensive publication strategy aligned with corporate and medical objectives, oversee the preparation and submission of scientific materials, ensure publications adhere to ethical and compliance standards, lead the development of medical communication materials for MSLs and other stakeholders, collaborate with cross-functional teams on educational tools, build and manage a publications team, partner with clinical and regulatory teams, and ensure all communications are accurate and consistent with guidelines.

Skills

Scientific communication

Medical writing

Publication planning

Manuscript development

Abstract and poster preparation

Scientific congress submission

Ethical and compliance standards

Cross-functional collaboration

Strategic planning

Operational excellence

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free